Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Solutions for off-label therapy].

W A Schmidt1

  • 1Rheumaklinik Berlin-Buch, Karower Strasse 11, 13125 Berlin, Germany. schmidt.wa@t-online.de

Zeitschrift Fur Rheumatologie
|December 3, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Early referral of patients with suspected polymyalgia rheumatica - A systematic review.

Seminars in arthritis and rheumatism·2023
Same author

Association of ultrasound-confirmed axillary artery vasculitis and clinical outcomes in giant cell arteritis.

Seminars in arthritis and rheumatism·2022
Same author

A study on echocardiographic findings in hospitalized patients with connective tissue diseases.

Scandinavian journal of rheumatology·2021
Same author

[S2k guidelines: management of large-vessel vasculitis].

Zeitschrift fur Rheumatologie·2020
Same author

[S2k guidelines (executive summary): management of large-vessel vasculitis].

Zeitschrift fur Rheumatologie·2020
Same author

[Imaging diagnostics in large vessel vasculitis].

Zeitschrift fur Rheumatologie·2019
Same journal

[Prevention strategies in rheumatoid arthritis : From primary prevention to targeted drug interception].

Zeitschrift fur Rheumatologie·2026
Same journal

Methodological concerns and data discrepancies in the indirect treatment comparison of belimumab and anifrolumab.

Zeitschrift fur Rheumatologie·2026
Same journal

Evaluating the comparative efficacy of belimumab vs. anifrolumab in systemic lupus erythematosus: a response.

Zeitschrift fur Rheumatologie·2026
Same journal

[Update: DMARDs for MGUS].

Zeitschrift fur Rheumatologie·2026
Same journal

[A potpourri of diagnoses-Unusual manifestations of a chronic inflammatory bowel disease : Case report].

Zeitschrift fur Rheumatologie·2026
Same journal

[Not measurable but immeasurably important : Fever-The leading symptom of ancient medical theory].

Zeitschrift fur Rheumatologie·2026
See all related articles

Approximately 25% of drug administrations are for unapproved uses, particularly in rheumatic diseases. Health insurance may cover these off-label treatments if no alternatives exist and efficacy is scientifically proven.

Area of Science:

  • Rheumatology
  • Pharmacology
  • Health Economics

Context:

  • Off-label drug use is prevalent, accounting for about 25% of administrations.
  • Rheumatic disease treatment frequently involves off-label drug indications.
  • Health insurance coverage for off-label use is conditional.

Purpose:

  • To explore the extent and implications of off-label drug use in rheumatic diseases.
  • To outline the criteria for health insurance reimbursement for unapproved drug therapies.

Summary:

  • A significant portion of drug administrations, around 25%, are for indications not officially approved.
  • Off-label prescribing is common in managing rheumatic conditions.
  • Insurance reimbursement for these treatments is feasible under specific conditions: absence of approved alternatives and documented scientific evidence of efficacy.

Related Experiment Videos

Impact:

  • Highlights the importance of off-label use in current medical practice, especially for rheumatic diseases.
  • Informs healthcare providers and patients about potential insurance coverage for off-label treatments.
  • Underscores the need for robust scientific evidence to support the use and reimbursement of unapproved drug therapies.